Mogamulizumab Q4week Dosing in Participants With R/R CTCL

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04745234.

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationKyowa Kirin, Inc.

• Primary ID0761-016
• Secondary IDsNCI-2021-11328
• ClinicalTrials.gov IDNCT04745234